Targeted Therapy for BRAF-Mutated Gliomas

Gliomas harbouring activating mutations in BRAF represent a distinct molecular subset within central nervous system tumours. The most prevalent alteration, BRAFV600E, drives constitutive activation of the MAPK signalling cascade, promoting unrestrained proliferation and survival. Targeted therapy has evolved rapidly from monotherapy with selective BRAF inhibitors to rational combinations incorporating MEK inhibitors designed to deepen pathway suppression and delay adaptive resistance. Clinical experience spans paediatric low- and high-grade gliomas through to adult cohorts, demonstrating that dual inhibition of BRAF and MEK can achieve meaningful response rates with manageable toxicity. Despite these advances, challenges remain in overcoming primary and acquired resistance that may arise through feedback activation of parallel pathways, secondary mutations or intratumoural heterogeneity. Ongoing efforts focus on refining patient selection through molecular stratification, identifying combinatorial regimens—including inhibitors of EGFR, PI3K–Akt–mTOR or immune checkpoints—and integrating liquid biopsy for early detection of resistance. The global significance of this approach lies in its potential to shift the treatment paradigm for patients traditionally reliant on surgery, radiotherapy and cytotoxic chemotherapy, offering a precision medicine strategy that can prolong progression-free intervals and improve quality of life.

Research from Nature Portfolio

Recent clinical data have demonstrated the tumour-agnostic activity of combined BRAF and MEK inhibition in patients with BRAFV600E-mutated gliomas. A phase 2 basket trial evaluated a BRAF inhibitor alongside a MEK inhibitor across multiple rare cancer cohorts including low-grade and high-grade glioma, reporting overall response rates above 50% in paediatric low-grade glioma and over 30% in high-grade glioma. Duration of response extended beyond a year in several glioma subgroups, and median progression-free survival ranged from 5 to 9 months. Safety profiles were consistent with known on-target effects such as pyrexia, rash and fatigue, underscoring the feasibility of this combination in central nervous system tumours. These results have paved the way for regulatory approvals and have set a benchmark for future studies exploring next-generation inhibitors and novel combination partners to overcome resistance.

Targeted Therapy for BRAF-Mutated Gliomas publication trend

The graph below shows the total number of articles in targeted therapy for braf-mutated gliomas across all publications each year (not limited to Nature Index journals).

Technical terms

BRAFV600E mutation: A substitution of valine (V) to glutamic acid (E) at codon 600 of BRAF that constitutively activates the protein kinase.

MAPK pathway: A signalling cascade involving RAF, MEK and ERK kinases that regulates cell proliferation and survival.

BRAF inhibitor: A small molecule that selectively inhibits mutated BRAF kinase activity.

MEK inhibitor: A compound that blocks MEK kinase, downstream of BRAF, to reinforce pathway suppression.

Progression-free survival: The interval during which a patient’s disease does not worsen under treatment.

References

1. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nature Medicine (2023).
2. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma. Journal of Clinical Oncology (2023).
3. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition. Neuro-Oncology (2024).
4. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. npj Precision Oncology (2023).